OncoMatch/Clinical Trials/NCT04414475
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Is NCT04414475 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Selinexor and Dexamethasone for multiple myeloma, refractory.
Treatment: Selinexor · Dexamethasone · Bortezomib — The purpose of this study is to assess the efficacy, antitumor activity, safety and tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
refractory to previous treatment with at least 2 proteasome inhibitors (PIs)
Must have received: immunomodulatory agent
refractory to previous treatment with at least 2 immunomodulatory agent (IMiDs)
Must have received: anti-CD38 monoclonal antibody
refractory to previous treatment with at least 1 anti-cluster of differentiation (CD38) monoclonal antibody
Cannot have received: SINE compound (selinexor)
Prior exposure to a SINE compound, including selinexor
Lab requirements
Blood counts
ANC < 1000/mm^3, platelet count < 75,000/mm^3, hemoglobin < 8.5 g/dL [excluded]
Kidney function
estimated creatinine clearance of < 20 mL/min, calculated using Cockroft and Gault [excluded]
Liver function
total bilirubin >= 2x ULN (>= 3x ULN for participants with Gilbert's syndrome), AST >= 2.5x ULN, and ALT >= 2.5x ULN [excluded]
Inadequate hepatic, renal, or hematopoietic function as defined in exclusion criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify